Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

被引：39

作者：

Walsh, Garry M. ^{[1
]}

机构：

[1] Univ Aberdeen, Inst Med Sci, Sch Med & Dent, Div Appl Med, Foresterhill, Aberdeen AB25 2ZD, Scotland

来源：

BIOLOGICS-TARGETS & THERAPY | 2013年 / 7卷

关键词：

IL-5; asthma; eosinophil;

D O I：

10.2147/BTT.S30133

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to - eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil T) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.

引用

页码：7 / 11

页数：5

共 36 条

[1] Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients [J].

Bateman, ND ;

Shahi, A ;

Feeley, KM ;

Woolford, TJ .

CLINICAL OTOLARYNGOLOGY, 2005, 30 (03) :221-225

[2] Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis [J].

Blanchard, C ;

Wang, N ;

Stringer, KF ;

Mishra, A ;

Fulkerson, PC ;

Abonia, JP ;

Jameson, SC ;

Kirby, C ;

Konikoff, MR ;

Collins, MH ;

Cohen, MB ;

Akers, R ;

Hogan, SP ;

Assa'ad, AH ;

Putnam, PE ;

Aronow, BJ ;

Rothenberg, ME .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (02) :536-547

[3]

Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016

[4] A striking local esophageal cytokine expression profile in eosinophilic esophagitis [J].

Blanchard, Carine ;

Stucke, Emily M. ;

Rodriguez-Jimenez, Beatriz ;

Burwinkel, Karen ;

Collins, Margaret H. ;

Ahrens, Annette ;

Alexander, Eileen S. ;

Buckmeier, Bridget K. ;

Jameson, Sean C. ;

Kaul, Ajay ;

Franciosi, James P. ;

Kushner, Jonathan P. ;

Putnam, Philip E. ;

Abonia, J. Pablo ;

Rothenberg, Marc E. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (01) :208-U341

[5] Biology of the Eosinophil [J].

Blanchard, Carine ;

Rothenberg, Marc E. .

ADVANCES IN IMMUNOLOGY, VOL 101, 2009, 101 :81-121

[6] EOSINOPHILIC INFLAMMATION IN ASTHMA [J].

BOUSQUET, J ;

CHANEZ, P ;

LACOSTE, JY ;

BARNEON, G ;

GHAVANIAN, N ;

ENANDER, I ;

VENGE, P ;

AHLSTEDT, S ;

SIMONYLAFONTAINE, J ;

GODARD, P ;

MICHEL, FB .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1033-1039

[7] Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study [J].

Castro, Mario ;

Mathur, Sameer ;

Hargreave, Frederick ;

Boulet, Louis-Philippe ;

Xie, Fang ;

Young, James ;

Wilkins, H. Jeffrey ;

Henkel, Timothy ;

Nair, Parameswaran .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (10) :1125-1132

[8] Structure and humanization of a rat monoclonal Fab to human interleukin-5 [J].

Cook, WJ ;

Walter, LJ ;

Murgolo, NJ ;

Chou, CC ;

Petro, M ;

Zavodny, PJ ;

Narula, SK ;

Ramanathan, L ;

Trotta, PP ;

Nagabhushan, TL .

PROTEIN ENGINEERING, 1996, 9 (07) :623-628

[9]

Corren J, 2012, DISCOV MED, V13, P305

[10] Eosinophilic esophagitis: management and pharmacotherapy [J].

De Angelis, P. ;

Morino, G. ;

Pane, A. ;

Torroni, F. ;

Francalanci, P. ;

Sabbi, T. ;

Foschia, F. ;

Caldaro, T. ;

di Abriola, G. Federici ;

Dall'Oglio, L. .

EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (05) :731-740

← 1 2 3 4 →